The role of BRCA1 gene polymorphism in patients with recurrent ovarian cancer

Scherbatykh Darya

In this article, we tried to determine the pathogenetic role of the BRCA1 gene polymorphic genotypes in patients with recurrent ovarian cancer. Relapse of ovarian cancer may be accompanied by the manifestation of changes in liver transaminases in the form of the development of endogenous intoxication, oxidative stress and hemostatic disorders. In patients with recurrent ovarian cancer with conditionally "mutant" polymorphisms 5382ins, 4153delA, and 185delAG of the BRCA1 gene, more pronounced and persistent changes in the indices of the homeostasis system are observed. It was also noted that the survival rate in these patients is sharply reduced. The therapeutic effectiveness of standard chemotherapy used in relapses of ovarian cancer in restoring the functional state of the homeostasis system occurs at a slower pace. We came to the conclusion that it is important for patients with ovarian cancer before treatment with chemotherapy, in addition to routine research methods, to analyze genetic polymorphisms (5382ins, 4153delA, 185delAG) of the BRCA1 gene for early progression of the disease.

Keywords:ovarian cancer, endotoxicosis, lipoperioidation, hemostasis, polymorphism, 5382ins, 4153delA, 185delAG, BRCA1.